We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BBI Launches Innovative Conjugate Blocking Technology
Product News

BBI Launches Innovative Conjugate Blocking Technology

BBI Launches Innovative Conjugate Blocking Technology
Product News

BBI Launches Innovative Conjugate Blocking Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BBI Launches Innovative Conjugate Blocking Technology "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lateral-flow-immunoassay_web.jpg

The technology, developed in-house by BBI Solutions scientists, improves the limit of detection of an assay, providing an increase in sensitivity of up to ten times and a faster time to result. 

Lateral flow immunoassays (LFIs) rely on the specific interaction between the analyte of interest and an immobilised binding partner, such as an antibody, antigen or enzyme. To improve performance, a ‘blocking’ agent is bound to unoccupied conjugation sites on the reporter label, preventing non-specific binding. However, the most commonly used conjugate blocker, BSA cross-reacts with human serum albumin-binding antibodies, bovine and other animal-origin targets, and exhibits lot-to-lot variability. Its relatively large size can also lead to steric hindrance affecting the detection of the target molecule. The proprietary Morffi technology overcomes these issues. Due to its size in comparison to BSA, it improves the availability of analyte-specific binding partners on the surface of the reporter label, increasing the signal intensity and sensitivity of the assay. Morffi has been successfully tested with over 30 conjugates to date, clearly demonstrating its suitability for a range of LFIs. Find out more in the BBI Solutions whitepaper entitled Morffi, Enhanced performance of a lateral flow assay. 

Advertisement